Table 1.

Patients’ Characteristics in the Pharmacokinetics Analysis

Parameter	Cohort, n = 57 n (%) or Median (Range)
Demographic data
Sex ratio M/F	24/33
Age at birth (GA weeks + daysa)	34 (28.7–39.4)
28 w – 29 w + 6 d	4 (7)
30 w – 33 w + 6 d	23 (40.3)
34 w – 36 w + 6 d	18 (31.6)
≥37 GA	12 (21.1)
Postnatal age at first visitb (months)	0.6 (0.2–2.9)
Body weight at first visitb (kg)	2.1 (0.9–4.7)
Height at first visitb (cm)	45.1 (34–55.5)
Intrauterine growthc
10th–90th percentile	38 (66.7)
<10th percentile	8 (14)
<3rd percentile	11 (19.3)
Postnatal age throughout the study (months)	2.3 (0.2–7.3)
Postmenstrual age throughout the study (months)	10.1 (7.2–15.8)
Body weight throughout the study (kg)	3.7 (0.9–9.3)
Height throughout the study (cm)	50.1 (34–73)
Clinical data
Ethnicity (Black/colored/other)	39/17/1
Infants born to HIV-infected mother	34 (59.6)
Treated with lopinavir	1 (1.8)
Treated with nevirapine	32 (56.1)
Treated with lamivudine	2 (3.5)
Treated with zidovudine	25 (43.9)
Treated with rifampicin	4 (7)
Biological data for all visits
Serum creatinine (mg/dL)	0.42 (0.2–0.85)
Hemoglobin (g/dL)	9.6 (7.6–12.6)
ALT (IU/L)	10 (3–30)
Pharmacological data
Samples per patient	12 (2–14)
No. of occasions per patient	6 (1–7)
Daily dosing regimen (mg/kg)	10.3 (2.9–38.3)
Treated with oral suspension	44 (77.2)
Treated with tablet	28 (49.1)
Pharmacogenomics data (NAT2 genotype)
Slow metabolizer	10 (17.5)
Intermediate metabolizer	26 (45.6)
Fast metabolizer	7 (12.3)
Unknown classification	4 (7)
Missing data	10 (17.5)

Abbreviations: ALT, alanine aminotransferase; GA, gestational age; HIV, human immunodeficiency virus; NAT2, N-acetyl transferase 2.

In sum, 28 weeks equal to 6.5 months, 30 weeks equal to 7 months, 34 weeks equal to 8 months, and 37 weeks equal to 8.6 months (term).

For 39 patients, the first visit was at birth.

Using the Fenton chart.